Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Quality Assurance of Depression Ratings in Psychiatric Clinical Trials.
Journal: Journal of clinical psychopharmacology
Published: December 23, 2024
NRX-101 (D-Cycloserine + Lurasidone) Is Active against Drug-Resistant Urinary Pathogens In Vitro.
Journal: Antibiotics (Basel, Switzerland)
Published: February 18, 2024
NRX-101, a Rapid-Acting Anti-Depressant, Does Not Cause Neurotoxicity Following Ketamine Administration in Preclinical Models.
Journal: International journal of toxicology
Published: May 24, 2023
NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial.
Journal: International journal of bipolar disorders
Published: May 04, 2023
D-cycloserine is not susceptible to self-administration using an intravenous self-administration model in male ketamine-habituated Sprague-Dawley rats.
Journal: Pharmacology, biochemistry, and behavior
Published: January 25, 2023
The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.
Journal: Critical care medicine
Published: August 31, 2022
Brief Report: Rapid Clinical Recovery From Critical Coronavirus Disease 2019 With Respiratory Failure in a Pregnant Patient Treated With IV Vasoactive Intestinal Peptide.
Journal: Critical care explorations
Published: January 12, 2022
Intracameral Antibiotics Reduce the Risk of Endophthalmitis after Cataract Surgery: Does the Preponderance of the Evidence Mandate a Global Change in Practice?
Journal: Ophthalmology
Published: October 26, 2015
Showing 1-12 of 12
Last Updated: 09/26/2026